Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Organon by Year
Organon — Proscar (finasteride — BPH) International sales ($M) ($M)
Merck Organon: $96,000,000M in FY2025, up 2.1% from a year earlier.
Latest, FY2025
96,000,000
Period ended Dec 31, 2025
Change on a year earlier
+2.1%
94,000,000 in FY2024
History
7 years
Since FY2019
Sources
4
Documents cited below
Where the FY2025 figure comes from
Source: Organon & Co. SEC Filing (0001628280-26-011125) ↗
Reported in Organon & Co. Form 10-Q / 10-K (CIK 0001821825).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Organon — Proscar (finasteride — BPH) International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 96,000,000 | +2.1% | Organon & Co. SEC Filing (0001628280-26-011125) ↗ |
| FY2024 | Dec 31, 2024 | 94,000,000 | -2.1% | Organon & Co. SEC Filing (0001821825-25-000006) ↗ |
| FY2023 | Dec 31, 2023 | 96,000,000 | -3.0% | Organon & Co. SEC Filing (0001821825-25-000006) ↗ |
| FY2022 | Dec 31, 2022 | 99,000,000 | -14.7% | Organon & Co. SEC Filing (0001821825-25-000006) ↗ |
| FY2021 | Dec 31, 2021 | 116,000,000 | -33.3% | Organon & Co. SEC Filing (0001821825-23-000003) ↗ |
| FY2020 | Dec 31, 2020 | 174,000,000 | -13.9% | Organon & Co. SEC Filing (0001821825-23-000003) ↗ |
| FY2019 | Dec 31, 2019 | 202,000,000 | – | Organon & Co. SEC Filing (0001821825-22-000002) ↗ |
Cite this data
StockData. (2026). Merck Organon ($M), annual FY2019–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn-proscar-intl
See every metric in the Merck KPI table. Data updated Oct 26, 2026.